Education
About Us
Working with TipRanks
Follow Us
Revive Therapeutics Ltd (TSE:RVV)
:RVV
RVV Stock Chart & Stats
C$0.01
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.01
C$0.00(0.00%)
Day’s Range― - ―
52-Week Range<C$0.01 - C$0.08
Previous CloseN/A
Volume2.50K
Average Volume (3M)285.50K
Market Cap
C$29.30M
Enterprise ValueC$30.54M
Total Cash (Recent Filing)C$30.95K
Total Debt (Recent Filing)C$68.18K
Price to Earnings (P/E)―
Beta-1.61
Next Earnings
May 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding418,564,270
10 Day Avg. Volume295,136
30 Day Avg. Volume285,498
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-2.43
Price to Sales (P/S)0.00
P/FCF Ratio-10.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Clinical-stage PipelineRevive is a clinical-stage therapeutics developer centered on psilocybin programs and drug repurposing. A concentrated, clinical-stage pipeline with proprietary and in-licensed assets supports long-term value creation via trial readouts, partnerships, or licensing outcomes over the next several months.
Improved Cash Burn TrendTrailing cash outflows have fallen materially versus prior multi‑million burn years, with TTM free cash flow around -$0.44M. A sustained reduction in burn extends runway, lowers immediate financing urgency, and improves odds of advancing clinical programs without immediate dilutive capital raises.
Very Low Absolute DebtWith only nominal reported debt (~$68K TTM), the company has limited fixed financial obligations. Low leverage reduces insolvency risk and gives management flexibility to prioritize R&D or pursue strategic partnerships before taking on meaningful interest-bearing liabilities.
Bears Say
No Revenue; Ongoing LossesThe company remains pre-revenue with a substantial TTM net loss (~-$10.8M). Without product sales, Revive must rely on financing or partners to fund operations; persistent losses erode capital and constrain the firm's ability to invest organically in multiple programs simultaneously.
Negative Equity And Weakened Balance SheetEquity turning negative and a materially reduced asset base signal capital depletion and weaker financial flexibility. Negative equity can restrict access to credit, complicate partner negotiations, and raise structural financing risk that affects strategy and operations over a multi‑month horizon.
Dependence On External FundingPersistent negative operating cash flow means the company cannot self-fund development and will need external capital to advance trials. Reliance on markets or financings increases dilution risk, may divert management focus, and is a durable vulnerability until commercial revenue or sustainable cash generation emerges.
Revive Therapeutics News
RVV FAQ
What was Revive Therapeutics Ltd’s price range in the past 12 months?
Revive Therapeutics Ltd lowest stock price was <C$0.01 and its highest was C$0.08 in the past 12 months.
What is Revive Therapeutics Ltd’s market cap?
Revive Therapeutics Ltd’s market cap is C$29.30M.
When is Revive Therapeutics Ltd’s upcoming earnings report date?
Revive Therapeutics Ltd’s upcoming earnings report date is May 29, 2026 which is in 72 days.
How were Revive Therapeutics Ltd’s earnings last quarter?
Revive Therapeutics Ltd released its earnings results on Feb 27, 2026. The company reported -C$0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.001.
Is Revive Therapeutics Ltd overvalued?
According to Wall Street analysts Revive Therapeutics Ltd’s price is currently Overvalued.
Does Revive Therapeutics Ltd pay dividends?
Revive Therapeutics Ltd does not currently pay dividends.
What is Revive Therapeutics Ltd’s EPS estimate?
Revive Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Revive Therapeutics Ltd have?
Revive Therapeutics Ltd has 418,564,270 shares outstanding.
What happened to Revive Therapeutics Ltd’s price movement after its last earnings report?
Revive Therapeutics Ltd reported an EPS of -C$0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 50%.
Which hedge fund is a major shareholder of Revive Therapeutics Ltd?
Currently, no hedge funds are holding shares in TSE:RVV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Revive Therapeutics Ltd
Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics for rare disorders and infectious diseases. The company offers cannabinoid pharmaceutical portfolio that focuses on rare inflammatory diseases. It is developing Bucillamine, which is in Phase 3 clinical study for the treatment of infectious diseases, including influenza and COVID-19; Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases; and cannabidiol for treating autoimmune hepatitis and ischemia and reperfusion injury from organ transplantation. Revive Therapeutics Ltd. has research collaboration agreements with PharmaTher Inc. for the development of psilocybin in the treatment of cancer and the discovery of other uses of undisclosed psychedelic compounds; North Carolina State University for the development of a biosynthetic version of psilocybin based on a natural biosynthesis enzymatic platform; the University of California, San Francisco to explore the use of Bucillamine as a treatment for severe COVID-19; University of Health Sciences Antigua for the clinical research of psychedelics; and PharmaTher for the development of psilocybin microneedle patch. The company was incorporated in 2012 and is headquartered in Toronto, Canada.
Technical Analysis
Options Prices
Currently, No data available
---